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Introduction: Few data are available on the safety of anticoagulation in very elderly patients treated with
Vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) for venous thromboembolism (VTE).
Methods: We carried out a prospective cohort study on VTE patients aged ≥85 years enrolled in the Survey on
anticoagulaTed pAtients RegisTer (START2-Register) on treatment with VKAs or DOACs, with the aim to
evaluate mortality, bleeding and thrombotic rates (venous and arterial).
Results: We enrolled 272 patients, 58.7% on VKA and 41.3% on DOACs. Baseline characteristics were similar
between treatment groups, with a higher prevalence of renal failure in VKAs patients and of a history of bleeding
and previous stroke/TIA in DOACs patients. During follow-up of 429 patient-years, 15 major and non-major
clinically relevant bleedings were recorded (rate 3.5× 100 pt-yrs), 5 were major bleeds (rate 1.2× 100 pt-yrs),
1 in a patient on aspirin (rate 4.3× 100 pt-yrs). Bleeding rate was higher in patients on DOACs (crude HR 4.7;
95%CI 1.5–15.01). Eight thrombotic events were recorded (rate 1.9×100 pt-yrs), 3 recurrent VTE and 5 stroke/
TIA. Overall, the incidence of thrombotic events was higher in DOACs patients (crude HR 4.5; 95% CI 1.5; 13.3).
The rate of recurrent VTE was similar in the two group. Mortality rate was significantly lower in DOACs patients
(crude HR 0.30; 95% CI 0.1;0.9).
Conclusion: A higher bleeding risk was found in very elderly VTE patients on DOACs despite the wide use of low-
dosages. Similarly a higher thrombotic risk was found while the incidence of recurrent VTE was low and similar
between the groups. Mortality rate were significantly lower in DOACs patients.
1. Introduction
The term “venous thromboembolism” (VTE) includes deep vein
thrombosis (DVT) of the lower limbs and/or pulmonary embolism (PE).
VTE is a common disease, especially in the elderly, and is associated
with increased risk of mortality, hospitalization and chronic compli-
cations such as post-thrombotic syndrome or chronic thromboembolic
pulmonary hypertension. A first episode of VTE confers a higher risk for
recurrences, therefore VTE must be considered a chronic disease.
Oral anticoagulation either with vitamin K antagonists (VKAs) or
direct oral anticoagulants (DOACs) has a proven efficacy in the short
and long-term prevention of VTE recurrences. However, the long-term
safety of anticoagulant treatment remains a matter of concern, in par-
ticular for elderly patients. No randomized-controlled trials (RCTs) of
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DOACs versus VKA were specifically designed to address this issue in a
population of elderly patients. A meta-analysis of clinical trials showed
that in patients aged 75 years or more, DOACs were more effective in
reducing VTE recurrences and safer than warfarin [1,2]. However, in
these RCTs elderly patients represented only about 12–15% of the
whole study populations, with the exception of the Recover II study
(20%) and the Resonate study (30%) [3].
Therefore, additional evidence is needed on the safety and effec-
tiveness of oral anticoagulant therapy (VKAs or DOACs) in very elderly
patients with acute VTE and for those who require extended treatment.
Moreover, it is worth collecting data from real-world patients about the
use of low-dose DOACs in this setting.
We have carried out a multicenter, prospective cohort study on
patients aged ≥85 years with a VTE event enrolled in the Survey on
anticoagulaTed pAtients RegisTer (START2-Register) who started a
treatment with either VKAs or DOACs to evaluate the type and duration
of anticoagulant therapy and the incidence of adverse events.
2. Methods
The START2-Register is an observational, multicenter, prospective
cohort study that includes adults (> 18 years) who start antic-
oagulation therapy, whatever the clinical indication for the therapy, the
drug and dosage used [4]. The aim of the START2-Register is to collect
data on effectiveness and safety of anticoagulant treatments, on de-
terminants of adverse events in anticoagulated patients, as well as on
their quality of life and compliance to treatment. The registry has been
approved on October 2011 (N=142/2010/0/0ss) by the Ethical
Committee of the Institution of the Coordinating Member (AziendaOs-
pedaliero-Universitaria, Policlinico S. Orsola-Malpighi, Bologna, Italy),
all patients gave their written informed consent before enrollment. The
study is registered in ClinicalTrials.gov Identifier: NCT02219984; it is
ongoing and actively recruiting. Here we present the results of the co-
hort of patients with venous thromboembolism (VTE) who started the
anticoagulation at the age ≥85 years. For the purpose of the present
analysis, data were collected from January 2012 to April 2018. VTE
events are considered as unprovoked if they are not temporally asso-
ciated with a major risk factor within 3months of diagnosis (surgery
with general or spinal anesthesia, lower limb fracture, casting or no
weight bearing for ≥3 days, bed-bound for 3 days due to acute illness),
or are associated with a minor risk factor [5].
All participating centers are asked to consecutively include patients
who start anticoagulant treatment, for any indication and with any
available drug, if this is planned to last for at least 3 months. Patients
with life-expectancy<6months, or not residents in the participant
region, or planning to leave in the next six months after enrolment are
not eligible, as well as patients already enrolled in phase II or III clinical
studies. Patients were followed-up during anticoagulant treatment, and
follow-up was stopped when the treatment was withdrawn. Participants
are required to enroll their patients consecutively, without any a priori
exclusion criteria other than life-expectancy or geographical in-
accessibility. Definition of the time-frame for enrolment (e. g. one week
every month, or the first month of the year) is left at each participant's
discretion, as long as it provides a random enrolment of patients.
Baseline patient's clinical features are recorded by participants on web-
based case report forms (CRF) and include: demographic and clinical
characteristics of patients, clinical indication for treatment, associated
risk factors for thromboembolic complications or bleeding occurring
during treatment, laboratory routine data, type of anticoagulant drug
used and dose (or expected therapeutic range), use of concomitant
drugs. For patients treated with VKA, all INR controls, the subsequent
dosing prescriptions and information at each visit about possible clin-
ical events and changes in the medical history are automatically cap-
tured via informatics. All INRs were recorded and time in therapeutic
range (TTR) [6] of the last 6 months of treatment was reported. Parti-
cipants are required to regularly follow-up all enrolled patients at least
quarterly, by phone call or ambulatory visit. An ambulatory follow-up
visit is mandatory at least annually. In the presence of severe dementia
or frequent falls or bed rest the patients were defined frail. Creatinine
clearance was calculated by the Cockroft-Gault formula [7]. Patients
are stratified for baseline bleeding risk evaluation according to HAS-
BLED score [8].
Major endpoints of the study were bleeding events, VTE recurrence,
and death for all causes. Major bleeding (MB) were defined as re-
commended by the International Society on Thrombosis and
Haemostasis [9]. Clinically relevant non-major bleeding (CRNMB) are
defined as any overt bleeding requiring a medical intervention (hospi-
talization, surgery or interventional procedure, further diagnostic
imaging, laboratory test or specialist evaluation) and/or treatment
discontinuation, and not meeting any of the criteria for major bleeding
[10].
Thromboembolic complications, such as new or recurrent DVT or PE
episodes, stroke, transient ischemic attack (TIA), peripheral embolism,
and acute myocardial infarction (AMI) are recorded. If not specified
differently in relation to specific study designs, thrombotic complica-
tions are adjudicated by the local investigators, based on clinical signs
and symptoms combined with objectively confirmed diagnostic radi-
ology and laboratory tests (color-Doppler ultrasound investigation,
magnetic resonance imaging, computed tomography, electro-
cardiography, laboratory markers). Death for all causes were con-
sidered; in particular death was defined as consequence of bleeding or
of thrombotic events or not related to anticoagulation in all the other
cases.
2.1. Statistical analysis
Data were described as the mean value and standard deviation (SD)
for continuous variables and proportions for categorical variables.
Differences between continuous values were assessed using the un-
paired t-test, categorical variables were compared by the Chi-square
test or Fisher exact test as appropriate.
The median and interquartile range (IQR) follow-up time were
calculated and the median test applied to test difference between
groups.
The incidences of death, thrombotic accidents, and bleeding events
were calculated by dividing the number of events by person time at risk.
The incidence rate ratio and together with the 95% confidence interval
(95%CI) were calculated.
The crude hazard ratios (HRs) with the 95%CI, and a multivariate
hazard model was calculated for the three outcomes. All analysis was
carried out using SAS statistical package (Version 9.4 for Windows. SAS
Institute Inc. Cary NC).
3. Results
The present study analyzed 272 patients who started antic-
oagulation at the age ≥85 years, and who were included in the
START2-Register during the interval time February 2012–April 2018
for the occurrence of a VTE episode. The baseline characteristics of the
whole population are detailed in Table 1. The mean age of patients was
88.1 years, and patients on DOACs were significantly older than pa-
tients on VKAs. Sixty-nine patients (25.4%) were aged ≥90 years at the
beginning of treatment. Patients were followed for a total period of 429
patient-years; 7 (2.6%) patients were lost at follow-up, 52 (19.0%)
patients stopped treatment after the established period of treatment, 12
(4.4%) stopped treatment for the onset of a contraindication; 32
(11.7%) patients still on treatment were no longer followed by the
participating centre.
The anticoagulant treatment was warfarin in 156 patients (57.3%)
and direct oral anticoagulants (DOACs) in 116 patients (42.7%), and 15
patients (5.5%) were also on treatment with antiplatelet drugs (9 with
low-dose aspirin, and 6 with clopidogrel), as reported in Table 2.
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Among DAOC patients 93, (80.2%) were naïve to treatment. Patients on
warfarin showed a median time in therapeutic range (TTR) of 68%
(interquartile range 54–79%); 52/116 (44.8%) patients on DOACs were
on treatment with the low dosage available for the treatment of acute
VTE for each drug.
The prevalence of patients with severe renal failure (creatinine
clearance< 30mL/min) was significantly higher in patients on war-
farin with respect to patients on DOACs. Conversely, the prevalence of
history of stroke/TIA and history of bleeding was significantly higher in
DOACs patients (Table 1). All other clinical characteristics were similar
between patients on warfarin and patients on DOACs (Table 1). Con-
comitant use of antiplatelet agents was also similar between the 2
treatment groups (Table 2).
The index event was deep vein thrombosis (DVT) in 148 patients
(54.4%), and VTE was unprovoked in 217 patients (79.8%), with a si-
milar distribution between patients on warfarin and patients on DOACs
(Table 3).
As shown in Table 4, during follow-up 15 major and CRNM bleeding
events were recorded in the whole study population (rate 3.5× 100 pt-
yrs); 5 events were major bleeding (rate 1.2× 100 pt-yrs), one of them
(gastrointestinal in a patient on warfarin) was fatal; 6/15 bleeding
events occurred among patients aged ≥90 years, all on DOACs treat-
ment. One major bleeding was recorded in patients concomitantly
treated with aspirin (rate 4.3×100 pt-yrs). Bleeding rates were higher
in patients on DOACs than in patients on VKAs (HR 4.0; 95%CI
1.3–13.6; p= 0.01). These results are confirmed also when the analysis
was limited to the first year of follow-up (Table 4). The difference was
confirmed at the multivariate model; 4 of 9 bleeding events in patients
treated with DOACs occurred on full dose treatment.
Overall, 8 thrombotic events were recorded during treatment (rate
1.9×100 pt-yrs); 2 were fatal (one each in patients on DOACs and on
warfarin) (Table 4). The rate of thrombotic events was significantly
higher in patients on DOACs than in patients on VKAs (HR 4.5; 95% CI
1.5–13.3); this difference was confirmed at the multivariate model and
when the analysis was limited to the first year. Only 3 of these events
were recurrences of VTE and no difference was detected between the 2
groups.
Mortality rates were lower in patients on DOACs than in those on
warfarin, with a HR of 0.30 (95% CI 0.1;0.9), confirmed at the multi-
variate model (Table 4). These results are confirmed also when the
analysis was limited to the first year of follow-up (HR 0.19, 95% CI
0.1–0.6).
4. Discussion
In this observational, prospective cohort study of very old patients
on anticoagulant treatment for VTE, the bleeding risk was low despite
the mean age of the population, with nearly 25% of patients older than
90 years at enrollment. The median duration of treatment was
19months, thus showing that elderly patients enrolled in this study are
maintained on anticoagulant treatment for a long period of time despite
clinical guidelines suggesting stopping anticoagulation after 3months
in patients at high risk of bleeding, such as very old patients.
When we looked at the type of anticoagulant drug used, we found
that patients on DOACs had higher rates of bleeding and also of
thrombotic complications with respect to patients on warfarin; how-
ever, their mortality rate was markedly reduced.
The two groups had different baseline characteristics, a finding that
is explained by the observational nature of the study. However, these
differences did not reach statistical significance in the majority of cases,
likely due to the relatively low number of enrolled patients. Patients on
DOACs were significantly older and with a more prevalent history of
previous bleeding or stroke/TIA events than patients on warfarin. On
Table 1
Clinical characteristics of patients.
All patients
(N=272)
VKA
(N=156)
DOACs
(N=116;
naive 93,
80.2%)
p Value
N% N% N%
Sex- female 178 (65.4) 99 (63.5) 79 (68.1) 0.4
Age (years) - mean (SD) 88.1 (3.0) 87.6 (2.3) 88.8 (3.7) 0.001
Weight < 60 kg 65 (23.9) 42 (26.9) 23 (19.8) 0.17
Follow-up (years) 429 312 117
Mean follow-up (months)
(SD)
19.1 (16.8) 24.3 (19.0) 12.2 (9.6) 0.01
Co-morbidity
Creatinine clearance
< 30mL/min
34 (12.5) 28 (17.9) 6 (5.2) 0.001
Creatinine clearance
30–50mL/min
150 (55.1) 83 (53.2) 67 (57.8) 0.46
Hemoglobin < 10 g/dL 12 (4.7) 7 (4.5) 5 (4.3) 1.0
Platelet count < 100,000 3 (1.1) 2 (1.3) 1 (0.9) 1.0
Chronic disease 16 (5.9) 10 (6.4) 6 (5.2) 0.8
Active cancer 11 (4.0) 9 (5.8) 2 (1.7) 0.2
Diabetes mellitus 36 (13.0) 16 (10.3) 20 (17.2) 0.1
Hypertension 191 (70.2) 114 (73.1) 77 (66.4) 0.2
Previous stroke/TIA 27 (9.9) 10 (6.4) 17 (14.7) 0.04
Previous bleeding 11 (4.0) 3 (1.9) 8 (6.9) 0.06
Coronary artery disease 29 (10.7) 19 (12.2) 10 (8.6) 0.4
Heart failure 18 (6.6) 11 (7.1) 7 (6.0) 0.8
POAD 18 (6.6) 9 (5.8) 9 (7.8) 0.6
COPD 38 (14.0) 24 (15.4) 14 (12.1) 0.5
Frail subjectsa 50 (18.4) 31 (19.9) 19 (16.4) 0.5
Bleeding risk stratification
scores
HASBLED - mean (SD) 2.0 (0.7) 2.05 (0.7) 2.0 (0.8) NS
a Patient with dementia or bed rest or prone to fall.
Table 2
Type of treatment and co-medications.
All patients
(N=272)
VKA
(N=156)
DOACs
(N=116)
p Value
N% N% N%
Type of anticoagulant drug
Warfarin 156 (100)
Apixaban 43 (37.1)
Dabigatran 5 (4.3)
Edoxaban 7 (6.0)
Rivaroxaban 61 (52.6)
Low-dose DOACs 52 (44.8)
Co-medications
Antiplatelet drugs 15 (5.5) 9 (5.8) 6 (5.2) 1.0
Proton pump inhibitor 127 (46.7) 79 (50.6) 48 (41.4) 0.8
Statins 43 (15.8) 19 (12.2) 24 (20.7) 0.1
Psychotropic drugs 48 (17.6) 30 (19.2) 18 (15.5) 0.6
Table 3
Characteristics of VTE index event.
All patients
(N=272)
VKA
(N=156)
DOACs
(N=116)
p Value
N% N% N%
Site of index event
DVT 148 (54.4) 82 (52.6) 66 (56.9) 0.5
DVT/PE 57 (21.0) 32 (20.5) 25 (21.6) 0.9
PE 67 (24.6) 42 (26.9) 25 (21.6) 0.3
Nature of index event (270/272
patients)
Unprovoked 217 (80.3) 126 (80.8) 91 (80.2) 0.2
Secondary to transient risk
factor
53 (19.7) 30 (19.2) 23 (19.8) 1.0
Recurrent VTE 28 (10.4) 14 (9.0) 14 (12.1) 0.4
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the contrary, as expected, severe renal failure was significantly more
represented among patients on warfarin. The higher rate of bleeding
observed in our DOACs cohort could be at least in part due to the higher
prevalence of previous bleeding events in this group of patients.
Similarly, the higher rate of previous cerebral ischemic events in this
group of patients could explain the higher rate of stroke/TIA. Coleman
et al. [11] reported data of a retrospective claim database analysis of
patients with VTE with a median age of about 82 years, were the in-
cidence of major bleeding was similar to that found in our cohort.
However, in this study no difference was recorded between DOACs and
VKAs. The low number of events recorded in our study could explain
this discrepancy, but it should be noted that the median age of our
patients was markedly higher, reaching about 88 years. Therefore, we
cannot exclude that the very high median age of our patients may play a
role in this observed difference.
It should be noted that only 5.5% of patients enrolled in our study
were also on treatment with aspirin; yet the major bleeding rate in this
group was three-fold higher than in patients without aspirin treatment.
Notwithstanding the generally low number of events recorded in the
present study, a low rate of recurrent VTE was recorded during treat-
ment in the two groups of patients, even if higher in patients on DOACs
than in those on warfarin.
The use of low-dose regimen has not been tested in the registrative
trials for the use of DOACs in acute VTE patients, with the exception of
Hokusai study [12]. We found that about 45% of cases in our popula-
tion were receiving a low-dose regimen even in the acute phase of the
disease. This wide use of low dose regimen did not seem to affect the
efficacy of treatment, considering that only two VTE recurrences were
recorded among DOACs group, both in patients on full dose regimen.
On the contrary, both the reported stroke/TIA events occurred in low-
dose DOACs treated patients. In relation to the dose regimens of
DOACs, we found that five out of nine bleeding events occurred in
patients treated with low doses, suggesting that these patients were not
protected from bleeding risk.
In our cohort, a much lower mortality rate was found among DOACs
treated patients. In RCTs studies comparing DOACs versus warfarin
treatment, no difference in mortality rate was found [13], but it should
be noted that these trials have been conducted among patients with a
median age highly younger than our patients. We may suggest that the
higher mortality rate observed in patients on VKAs could be related, at
least in part, to the selection criteria adopted by physicians in deciding
the choice between the two anticoagulant regimens. In fact, the more
complex clinical conditions of VKAs patients and the prevalence of
severe renal failure may be one factor to explain the higher mortality
rate recorded in these patients.
This study has a number of limitations. Firstly, the observational
design requires extreme caution in interpreting direct comparisons
between drugs due the intrinsic limitations and high risks of bias of
these studies. Secondly, frailty was defined by using clinical items for
dementia, bed rest and frequent falls that could be easily reported by
the investigators, without the use of a validated, structured frailty
stratification score. This explains the relatively low rate of the indicated
items recorded in our cohort, where only very severe frailties were
recorded. Third, the causes of death reported in the electronic files
aimed to identify deaths related to bleeding events or cerebral ischemic
events. All other causes of death have been defined as not related to
anticoagulant treatment, including cancer, infectious diseases, vascular
events (not cerebral), heart failure, renal failure, respiratory in-
sufficiency, or sudden death. Finally, there was no central adjudication
of outcome events in this study.
5. Conclusion
In conclusion, notwithstanding the long period of treatment widely
adopted in Italian clinical practice - as it was in our cohort, we found
that the rate of bleeding and thrombotic complications among very
elderly VTE patients treated with oral anticoagulants was rather low.
Patients treated with DOACs, despite a wide use of low-dose treatment,
seemed to have a higher risk for bleeding than patients on warfarin.
However, the DOACs low-dose regimens seemed to protect adequately
the very elderly patients against VTE recurrence. Mortality was mark-
edly lower in patients receiving DOACs.
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Table 4
Adverse events during treatment.
VKA
(N=156)
DOACs
(N=116)
Univariate Multivariatea
N (x 100 pt-yrs) N (x 100 pt-yrs) HR (95%CI) HR (95%CI)
Bleeding events 6 (1.9) 9 (7.7) 4.7(1.5;15.0) 7.5(2.4;23.6)
Bleeding events at 12months 1 3 5.1 (0.6;42.1) 6.2 (0.5;71.7)
Major bleedings 2 (0.6) 3 (2.6)
Cerebral 1 0
Gastrointestinal 1c 3
CRNM bleedings 4 (1.3) 6 (5.1)d
Soft tissue ematoma 1 2
Gastrointestinal 2 1
Other 1 3
Thrombotic events 4 (1.3) 4 (3.4) 4.5 (1.5;13.3) 5.7 (1.6;20.3)
Thrombotic events at 12months 0 4 – –
Recurrent VTE 1 (0.3) 2 (1.7)
Arterial events 3 (1.0) 2 (1.7)b
Death for all causes 50 (16.0) 5 (4.3) 0.3 (0.1;0.9) 0.30(0.1;0.8)
Death at 12months 15 3 0.33 (0.10;1.13) 0.19 (0.06;0.55)
a Adjusted for: age at enrollment, Sex, Diabetes mellitus, Hypertension, Frailty; COPD, Previous bleeding, Previous stroke, Active cancer, Renal Failure.
b Both patients treated with low-dose DOACs.
c fatal.
d 5 patients on low-dose regimen.
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